Overview

Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Status:
Unknown status

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

Allo - hematopoietic stem cell transplantation is currently the only way to cure myelodysplastic syndrome /acute leukemia . The existing experimental results showed that decitabine and 5-azacytidine up-regulated the expression of tumor Ags on leukemic blasts in vitro and expanded the numbers of immunomodulatory T regulatory cells in animal models. Reasoning that decitabine might selectively augment a graft versus leukemia effect, the investigators used decitabine administration after allogeneic stem cell transplantation to studied the immunologic sequelae.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

The First Affiliated Hospital of Soochow University

Collaborator:

Xian-Janssen Pharmaceutical Ltd.

Treatments:

Azacitidine
Decitabine